Does Sharp Health Plan Cover Prolia?

What Sharp Health Plan Actually Says About Prolia Coverage

Sharp Health Plan covers Prolia for osteoporosis in most of its plan designs, but coverage is not automatic. The drug almost always sits on a Tier 3 or Tier 4 formulary position, meaning it is subject to prior authorization (PA) and, in many plans, mandatory step therapy. PA is a formal review process in which your prescribing physician documents that Prolia is medically necessary for your specific clinical situation before Sharp will agree to pay.

Prolia (denosumab) works by inhibiting RANK ligand, a protein that drives osteoclast-mediated bone resorption. The FDA approved it in June 2010 specifically for postmenopausal women with osteoporosis at high fracture risk, defined in labeling as a T-score of -2.5 or below, or a history of osteoporotic fracture [1]. Sharp's medical criteria for coverage largely mirror those FDA-approved indications, though each plan year's Evidence of Coverage document may refine eligibility.

How the Formulary Tier Affects Your Cost

Most Sharp commercial plans place Prolia on Tier 3 (preferred brand) or Tier 4 (non-preferred brand/specialty). On a Tier 4 specialty benefit, a member might pay a percentage of the drug's list price rather than a flat copay. The FDA-approved list price for one 60 mg prefilled syringe is approximately $1,400, making a 30% coinsurance roughly $420 per dose before any manufacturer assistance.

Employer-sponsored Sharp plans negotiated through the California School Employees Association or county government contracts may have different tier placements and lower specialty tiers. Always check the current Summary of Benefits and Coverage document for the exact plan year.

Medicare Advantage vs. Commercial Plans

Sharp's Medicare Advantage products follow Part B billing rules for Prolia. Because Prolia is physician-administered (given in-office or at an infusion center), it bills under Medicare Part B as a medical benefit rather than a pharmacy benefit. This distinction matters: Part B cost-sharing typically means 20% coinsurance after the Part B deductible, rather than a pharmacy copay. Sharp's Medicare Advantage plans may reduce that 20% to a fixed dollar amount, so check your Medicare Advantage Evidence of Coverage.

Prior Authorization Requirements for Prolia Under Sharp Health Plan

Prior authorization for Prolia under Sharp Health Plan generally follows evidence-based osteoporosis management criteria. Your physician will need to submit clinical documentation supporting medical necessity [2].

Typical Documentation Sharp Requires

Sharp's PA criteria (and those of its pharmacy benefit manager) typically require your physician to provide:

• A bone density (DEXA) scan result showing a T-score of -2.5 or lower at the lumbar spine, total hip, or femoral neck, OR a documented fragility fracture
• A diagnosis of osteoporosis confirmed by a physician, and not merely osteopenia
• Documentation of an adequate trial of a bisphosphonate (most commonly alendronate 70 mg weekly for at least 12 months) unless there is a documented clinical reason why bisphosphonates are contraindicated or not tolerated
• For glucocorticoid-induced osteoporosis: documentation of systemic corticosteroid use of at least 7.5 mg/day prednisone equivalent for 3 or more months

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) guidelines state that pharmacologic therapy is indicated for postmenopausal women and men aged 50 and older who have a hip or vertebral fracture, a T-score of -2.5 or below, or a 10-year probability of hip fracture of 3% or greater by FRAX [3].

Step Therapy: The Bisphosphonate-First Requirement

Many Sharp commercial plans require step therapy, meaning you must try and fail (or have a documented contraindication to) an oral bisphosphonate before Prolia is approved. Alendronate (generic Fosamax) and risedronate (generic Actonel) are the most common first-step agents because they are inexpensive generics available for as little as $4-$10 per month.

Valid reasons to bypass step therapy and go directly to Prolia include:

• Esophageal dysmotility, stricture, or achalasia (contraindication to oral bisphosphonates)
• Inability to sit or stand upright for 30 minutes after taking an oral bisphosphonate
• Severe renal impairment (estimated GFR below 35 mL/min/1.73 m², at which point oral bisphosphonates carry higher risk)
• Documented intolerance such as GI ulceration confirmed by endoscopy
• Atypical femur fracture associated with prior bisphosphonate use

Your physician should explicitly state one of these reasons in the PA submission. Vague language like "patient prefers injections" is rarely sufficient.

The Clinical Evidence Behind Prolia That Supports Coverage Approval

Understanding the trial data helps both patients and prescribers frame the medical necessity argument accurately when seeking PA approval.

FREEDOM Trial: The Core Efficacy Data

The FREEDOM trial (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) enrolled 7,808 postmenopausal women with osteoporosis and followed them for 36 months. Denosumab 60 mg subcutaneously every 6 months reduced new vertebral fracture risk by 68% compared with placebo (P<0.001), hip fracture risk by 40% (P=0.04), and nonvertebral fracture risk by 20% (P=0.01) [4]. These are the numbers your physician can cite directly in a PA submission to demonstrate clinical necessity.

FREEDOM Extension: Long-Term Safety

The FREEDOM open-label extension followed participants out to 10 years. Women who received continuous denosumab for 10 years showed further gains in lumbar spine bone mineral density (BMD) of 21.7% from baseline, with a low rate of atypical femur fractures and osteonecrosis of the jaw [5]. Long-term efficacy and a well-characterized safety profile strengthen the medical necessity argument for patients who have already been on Prolia for multiple years.

FRAX-Based Prescribing and Coverage Thresholds

The FRAX tool, developed at the University of Sheffield and endorsed by the International Osteoporosis Foundation and the BHOF, calculates 10-year fracture probability using clinical risk factors with or without BMD. Many Sharp PA reviewers and their pharmacy benefit managers use FRAX thresholds of a 3% 10-year hip fracture probability or a 20% 10-year major osteoporotic fracture probability as coverage triggers for initiating pharmacotherapy [3]. A FRAX calculation showing values above those thresholds, submitted with the PA, strengthens the approval case considerably.

What Happens If Sharp Denies Your Prolia Prior Authorization

A denial is not a final answer. California law and federal rules give you specific appeal rights, and denials are frequently overturned when a physician submits targeted additional documentation.

Step 1: Request the Denial Letter and Criteria

Sharp must provide a written denial that cites the specific clinical criteria your case did not meet. California Health and Safety Code Section 1367.01 requires managed care plans to issue denial notices that explain the clinical basis for the decision. Read the denial carefully to identify the precise gap in documentation.

Step 2: File an Internal Appeal

You or your physician may file an internal appeal within 180 days of the denial. For urgent clinical situations (for example, a patient with a recent hip fracture), California law requires a decision on an expedited appeal within 72 hours.

Step 3: Request an Independent Medical Review

If Sharp upholds the denial after internal appeal, California law entitles you to a free Independent Medical Review (IMR) by the Department of Managed Health Care (DMHC). The IMR is conducted by board-certified specialists who have no financial relationship with Sharp. Nationally, IMR processes overturn insurer denials at a meaningful rate, particularly when additional clinical documentation accompanies the request [6].

Step 4: Contact Your Physician for a Peer-to-Peer Review

Requesting a peer-to-peer (P2P) review allows your prescribing physician to speak directly with the Sharp medical director reviewing the case. Studies published in peer-reviewed literature show that P2P calls resolve a significant proportion of PA denials before a formal appeal is necessary [7]. Your physician's office staff can initiate this call.

How Much Does Prolia Cost With Sharp Health Plan?

Cost varies significantly by plan type, tier placement, and whether you qualify for manufacturer assistance.

Commercial Plan Cost-Sharing

On commercial Sharp plans with a specialty tier:

• Flat copay plans: $50-$200 per 60 mg injection (every 6 months)
• Coinsurance plans: 20%-30% of the negotiated rate, which may be $200-$500+ per dose without assistance
• Out-of-pocket maximum protection: Once you hit your plan's annual out-of-pocket maximum, Sharp pays 100% for the rest of the benefit year

Amgen SupportPlus Copay Card

Amgen offers the Prolia SupportPlus program for commercially insured patients. Eligible patients may pay as little as $0 per dose, with Amgen covering up to a specified annual dollar maximum above any copay. Government-insured patients (Medicare, Medicaid, TRICARE) are not eligible for the copay card, but may qualify for the Amgen Safety Net Foundation for income-based assistance.

Medicare Advantage Cost-Sharing for Prolia

Because Prolia bills under Part B when physician-administered, Medicare Advantage members typically face:

• 20% coinsurance after the Part B deductible ($240 in 2024) under standard Medicare
• Sharp Medicare Advantage plans may cap the coinsurance at a fixed dollar amount per administration

For 2024, the Medicare-allowed amount for a 60 mg denosumab injection (CPT/HCPCS code J0897) is approximately $1,080, making the 20% share around $216 per dose [8].

How Prolia Compares to Alternative Osteoporosis Therapies Covered by Sharp

When step therapy requires you to try something else first, knowing your options matters.

Bisphosphonates (First-Line, Generic, Low Cost)

Alendronate 70 mg weekly is the most prescribed first-line agent in the U.S. The Fracture Intervention Trial (FIT, N=2,027) showed alendronate reduced vertebral fracture risk by 47% at 3 years in women with a prior vertebral fracture [9]. Generic alendronate costs under $10/month on most plans and usually requires no PA.

Risedronate 35 mg weekly showed a 41% relative risk reduction in vertebral fractures in the VERT-MN trial (N=1,628) at 3 years [10]. Also available as an inexpensive generic.

Zoledronic Acid (IV Bisphosphonate, Annual Infusion)

Zoledronic acid (Reclast) 5 mg IV annually showed a 70% reduction in vertebral fractures and a 41% reduction in hip fractures in HORIZON-PFT (N=7,765) [11]. Given intravenously once per year, it solves the oral tolerance problem. Sharp typically covers it under the medical benefit, similar to Prolia, and it also requires PA. However, it avoids the every-6-month injection schedule and is often lower cost than Prolia.

Romosozumab (Evenity)

Romosozumab 210 mg monthly for 12 months is a sclerostin inhibitor that both increases bone formation and decreases resorption. The ARCH trial (N=4,093) showed a 48% reduction in vertebral fracture risk versus alendronate at 24 months [12]. Sharp covers it on similar specialty-tier terms to Prolia. It carries an FDA boxed warning for increased cardiovascular risk and is contraindicated within 12 months of a myocardial infarction or stroke.

Teriparatide and Abaloparatide (Anabolic Agents)

Teriparatide (Forteo) 20 mcg daily subcutaneously for up to 24 months and abaloparatide (Tymlos) 80 mcg daily are anabolic agents reserved for very high fracture risk. Both require PA under Sharp and are typically more expensive than Prolia. Following anabolic therapy, anti-resorptive treatment (Prolia or a bisphosphonate) is required to maintain the bone gains [13].

What Your Physician Should Include in the Prolia PA Submission to Sharp

A well-constructed PA submission cuts the likelihood of denial. The following checklist reflects the documentation standard supported by BHOF clinical practice guidelines [3]:

1. Current DEXA scan results with T-scores at the lumbar spine and hip (scan must typically be within 24 months)
2. FRAX 10-year fracture probability calculation, ideally with femoral neck BMD entered
3. ICD-10 diagnosis code (M81.0 for age-related osteoporosis without current pathological fracture; M80.00 for age-related osteoporosis with pathological fracture)
4. Documentation of bisphosphonate trial with dates, doses, and outcome, OR explicit clinical reason for contraindication
5. A clear statement from the physician that Prolia is medically necessary for fracture risk reduction
6. Any prior fracture history with dates and imaging reports
7. Relevant comorbidities: renal function (eGFR), history of GERD or esophageal disease, calcium and vitamin D levels
8. Patient's current calcium and vitamin D supplementation (Prolia labeling requires adequate calcium and vitamin D before and during treatment)

Hypocalcemia must be corrected before initiating Prolia, per FDA prescribing information [1]. Documenting current serum calcium levels in the PA helps demonstrate clinical readiness.

Monitoring Requirements While on Prolia

Coverage approval is step one. Staying covered for subsequent doses requires adherence to monitoring protocols that Sharp may audit through its care management programs.

Every-6-Month Injection Schedule

Prolia must be administered every 6 months without delay. Delaying an injection beyond 7 months significantly increases fracture risk during the gap period because osteoclast activity rebounds sharply when denosumab clears [14]. Sharp's PA is typically approved for one year (two doses). Renewal PA is required annually and requires updated clinical documentation.

Lab Monitoring

• Serum calcium: before each dose and per clinical judgment
• Renal function: periodic monitoring, especially in patients with CKD
• Dental evaluation: before initiating therapy, given the low but real risk of osteonecrosis of the jaw (ONJ)

The American Association of Oral and Maxillofacial Surgeons estimates ONJ incidence in patients receiving denosumab for osteoporosis at approximately 0.001%-0.01% per year of exposure, far lower than in oncologic doses [15].

Discontinuation Planning

Do not stop Prolia without a transition plan. The BHOF and the American Society for Bone and Mineral Research both recommend transitioning to a bisphosphonate after stopping Prolia to prevent rapid bone loss and rebound vertebral fractures [14]. Sharp's coverage for the transition agent (typically zoledronic acid or alendronate) should be confirmed before Prolia is discontinued.